| Target General Infomation |
| Target ID |
T39610
|
| Former ID |
TTDS00432
|
| Target Name |
Calmodulin
|
| Synonyms |
CALM2; CaM
|
| Target Type |
Successful
|
| Disease |
Cardiac arrhythmias [ICD9: 427; ICD10: I47-I49] |
|---|
|
Malaria [ICD10: B54] |
|
Schizophrenia; Generalized non-psychotic anxiety [ICD10: F20] |
| Function |
Calmodulin mediates the control of a largenumber of enzymes by ca(2+). Among the enzymes to be stimulated by the calmodulin-ca(2+) complex are a number of protein kinases and phosphatases.
|
| BioChemical Class |
Calmodulin-dependent secretion
|
| Target Validation |
T39610
|
| UniProt ID |
|
| Sequence |
MADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVDADG
NGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKLTDE
EVDEMIREADIDGDGQVNYEEFVQMMTAK
|
| Drugs and Mode of Action |
| Drug(s) |
Aprindine |
Drug Info |
Approved |
Cardiac arrhythmias |
[1] |
|---|
| Halofantrine |
Drug Info |
Approved |
Malaria |
[2] |
| Trifluoperazine |
Drug Info |
Approved |
Schizophrenia; Generalized non-psychotic anxiety |
[3] |
| Inhibitor |
2-Methyl-2,4-Pentanediol |
Drug Info |
[4] |
|---|
| 2-Methyl-2-Propanol |
Drug Info |
[4] |
| Acetate Ion |
Drug Info |
[4] |
| Aprindine |
Drug Info |
[5] |
| Cacodylate Ion |
Drug Info |
[4] |
| MYRISTIC ACID |
Drug Info |
[6] |
| N-Trimethyllysine |
Drug Info |
[4] |
| Trifluoperazine |
Drug Info |
[7] |
| Modulator |
Halofantrine |
Drug Info |
[8] |
|---|
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) |
| TEP |
EXP Info
|
| Pathways |
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Phosphatidylinositol signaling system
|
|
Oocyte meiosis
|
|
Adrenergic signaling in cardiomyocytes
|
|
Vascular smooth muscle contraction
|
|
Circadian entrainment
|
|
Long-term potentiation
|
|
Neurotrophin signaling pathway
|
|
Dopaminergic synapse
|
|
Olfactory transduction
|
|
Phototransduction
|
|
Inflammatory mediator regulation of TRP channels
|
|
Insulin signaling pathway
|
|
GnRH signaling pathway
|
|
Estrogen signaling pathway
|
|
Melanogenesis
|
|
Oxytocin signaling pathway
|
|
Glucagon signaling pathway
|
|
Salivary secretion
|
|
Gastric acid secretion
|
|
Alzheimer'
|
|
s disease
|
|
Amphetamine addiction
|
|
Alcoholism
|
|
Pertussis
|
|
Tuberculosis
|
|
Glioma
|
|
NetPath Pathway
|
RANKL Signaling Pathway
|
|
TSH Signaling Pathway
|
|
PANTHER Pathway
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
BCR signaling pathway
|
|
p38 MAPK signaling pathway
|
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
Role of Calcineurin-dependent NFAT signaling in lymphocytes
|
|
IL2 signaling events mediated by PI3K
|
|
IFN-gamma pathway
|
|
Lissencephaly gene (LIS1) in neuronal migration and development
|
|
ErbB1 downstream signaling
|
|
VEGFR1 specific signals
|
|
Regulation of cytoplasmic and nuclear SMAD2/3 signaling
|
|
Calcium signaling in the CD4+ TCR pathway
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Insulin-mediated glucose transport
|
|
N-cadherin signaling events
|
|
Cellular roles of Anthrax toxin
|
|
Regulation of Ras family activation
|
|
Downstream signaling in na&
|
|
#xef
|
|
ve CD8+ T cells
|
|
PathWhiz Pathway
|
Muscle/Heart Contraction
|
|
Reactome
|
Calmodulin induced events
|
|
Platelet degranulation
|
|
Translocation of GLUT4 to the plasma membrane
|
|
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
|
|
DARPP-32 events
|
|
eNOS activation
|
|
Inactivation, recovery and regulation of the phototransduction cascade
|
|
FCERI mediated Ca+2 mobilization
|
|
Ca2+ pathway
|
|
CREB phosphorylation through the activation of CaMKII
|
|
Ras activation uopn Ca2+ infux through NMDA receptor
|
|
Smooth Muscle Contraction
|
|
VEGFR2 mediated vascular permeability
|
|
VEGFR2 mediated cell proliferation
|
|
RHO GTPases activate IQGAPs
|
|
RAF/MAP kinase cascade
|
|
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
WikiPathways
|
Translocation of GLUT4 to the Plasma Membrane
|
|
Visual phototransduction
|
|
Fc epsilon receptor (FCERI) signaling
|
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
|
Signaling by the B Cell Receptor (BCR)
|
|
Inositol phosphate metabolism
|
|
DAG and IP3 signaling
|
|
Opioid Signalling
|
|
Muscle contraction
|
|
Metabolism of nitric oxide
|
|
Metabolism of carbohydrates
|
| References |
| REF 1 | Appropriate dosing of antiarrhythmic drugs in Japan requires therapeutic drug monitoring. J Clin Pharm Ther. 2005 Feb;30(1):5-12. |
|---|
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020250. |
|---|
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
|---|
| REF 4 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. |
|---|
| REF 5 | Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):151-6. |
|---|
| REF 6 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. |
|---|
| REF 7 | Inhibitory effect of jujuboside A on glutamate-mediated excitatory signal pathway in hippocampus. Planta Med. 2003 Aug;69(8):692-5. |
|---|
| REF 8 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. |
|---|
